"Fast and Furious" Development of Novel Approaches Changes Face of Myeloma Treatment

Jessica Hergert
Published: Wednesday, Dec 04, 2019
Edward A. Stadtmauer, MD, section chief of hematologic malignancies and professor of medicine at the University of Pennsylvania Abramson Cancer Center

Edward A. Stadtmauer, MD

In an era of personalized medicine in oncology, monoclonal antibodies, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing patient outcomes in multiple myeloma, said Edward A. Stadtmauer, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication